Incidence and outcomes of atrial arrhythmia with cyclin dependent kinase 4/6 inhibitors in hormone receptor-positive / human epidermal growth factor receptor 2-negative breast cancer
Patients who receive CDK4/6 inhibitors for breast cancer experience a low but measurable risk of new-onset atrial arrhythmias. There was no significant difference in new-onset AA risk between agents. Prospective studies are needed to define mechanisms and guide monitoring strategies.
Authors
- Johannes M. Herrmann (ORCID: https://orcid.org/0000-0003-2081-4506)
- Nathaniel E Davis (ORCID: https://orcid.org/0009-0006-5656-5571)
- Nicholas Y. Tan (ORCID: https://orcid.org/0000-0002-0365-9471)
- Sophia G. Blumenfeld (ORCID: https://orcid.org/0009-0009-3783-343X)
- Kathryn J. Ruddy
- David O. Hodge
Institutions
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- International Journal of Cardiology
- Published
- 2026-03-01
- DOI
- https://doi.org/10.1016/j.ijcard.2026.134466
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 0.00